Frontlight ResearchEarly access
Not yet taking people in PolandPhase 4
Tests venetoclax with rituximab in adults with relapsed chronic lymphocytic leukemia
Tests venetoclax with rituximab in adults with returning chronic lymphocytic leukemia.
Key facts
- Who runs it
- Uniwersytet Medyczny W Lublinie
- Where
- Bydgoszcz, Lodz, Lublin, Warsaw, and Wroclaw, PolandSee the 6 sites
- Trial code
- Registry title
- Phase IV VR in relapsed CLL – Polish experience
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 36 people, planned
- Started
- 1 Apr 2026
- Expected to end
- 30 Nov 2027
- Type of study
- Interventional
- Record updated
- 26 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are starting treatment with venetoclax + rituximab (VR).
- Age
- Over 18 years
- Sex
- Men and women can join.
- Disease stage
- CLL or SLL that meets the 2018 iwCLL criteria, with a reason to start treatment and a fitness level (ECOG) of 0-2. Patients must qualify for treatment under the B.79 drug program.
- Earlier treatment
- Earlier treatment for CLL or SLL is required. If venetoclax was used before, the patient must have responded and the last dose must have been more than 36 months ago.
- Biomarker or test result
- Blood tests must show enough blood cells and normal kidney and liver function: hemoglobin ≥ 9 g/dL, neutrophils ≥ 1.0 × 109/L, platelets ≥ 75 × 109/L, creatinine clearance ≥ 30 mL/min/1.73 m², AST and ALT ≤ 2.5 × ULN, total bilirubin ≤ 1.5 × ULN.
Main reasons for not taking part
- Pregnancy or breastfeeding
- Active, severe infection
- Disease getting worse during treatment, including change into a more aggressive lymphoma
- Active hemolytic anemia that needs treatment, or autoimmune problems that needed high-dose steroids
- Current corticosteroid use (low doses under 10 mg prednisone for other conditions are allowed)
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- Age > 18 years
- Exclusion of pregnancy and breastfeeding
- Patient consent to contraception in accordance with the relevant, current Summary of Product Characteristics
- Absence of active, severe infections
- Absence of significant comorbidities or clinical conditions constituting a contraindication to therapy, as determined by the attending physician based on the relevant, current Summary of Product Characteristics
- Adequate organ function, determined on the basis of laboratory blood test results, enabling, in the opinion of the attending physician, safe commencement of therapy
- Prior treatment for CLL or SLL, including chemotherapy, BTK inhibitor therapy, venetoclax, small molecule signaling inhibitor, or monoclonal antibody therapy with response to previous venetoclax treatment > 36 months from last dose
- Adequate hematologic function independent of growth factors or transfusion support, according to the local laboratory reference range at screening (unless due to underlying disease, as evidenced by extensive bone marrow involvement or hypersplenism secondary to splenic lymphoma according to the investigator), defined as follows: • Hemoglobin ≥ 9 g/dL • Absolute neutrophil count ≥ 1.0 × 109/L • Platelet count ≥ 75 × 109/L
- Adequate renal function, according to the local laboratory reference range at screening, as indicated by: Calculated creatinine clearance ≥ 30 mL/min/1.73 m² using 24-hour creatinine clearance or the modified Cockcroft-Gault equation (eCCR; using ideal body weight [IBM] instead of weight)
- Normal liver function, according to the local laboratory reference range for screening, as indicated by: • AST and ALT ≤ 2.5 × ULN • Total bilirubin ≤ 1.5 × ULN (or ≤ 3 × ULN in patients with documented Gilbert's syndrome)
- Absence of active hemolytic anemia requiring immunosuppressive or other pharmacological treatment. Patients with a positive Coombs test but no evidence of hemolysis are NOT excluded from participation in the study
- Obtaining the patient's informed voluntary consent to participate in the study
- No current use of corticosteroids. EXCEPTION: Low-dose steroids (<10 mg prednisone or equivalent dose of another steroid) are permitted for the treatment of non-hematological conditions (e.g., chronic adrenal insufficiency)
- No prior autoimmune complications (e.g., autoimmune hemolytic anemia or immune thrombocytopenia) that have developed since the initial diagnosis of CLL and required treatment with high-dose corticosteroids (e.g., equivalent to >20 mg prednisone daily), monoclonal antibody-based therapy, or chemotherapy. Previous use of corticosteroids for reasons other than the treatment of autoimmune complications of CLL is permitted
- No major surgery within 4 weeks (28 days) of the first dose of study drug or minor surgery within 3 days of the first dose of study drug
- No radiotherapy ≤ 4 weeks before starting study treatment
- The patient must be able to take a xanthine oxidase inhibitor or rasburicase for tumor lysis syndrome (TLS) prophylaxis
- Negative pregnancy test result (serum βHCG concentration) for women of reproductive age (including premenopausal women who have had tubal ligation) and for all women who do not meet the definition of postmenopausal (≥ 24 months of amenorrhea) and who have not undergone surgical sterilization through hysterectomy and/or bilateral oophorectomy. For all other women, documentation confirming that the patient is not of reproductive age should be provided in the medical interview. ● Patients who are not surgically sterile or postmenopausal must agree to the simultaneous use of two reliable forms of contraception or to complete abstinence from heterosexual intercourse during the study. ● Men must agree to use a latex condom during sexual contact with women of reproductive age during the study and for at least 28 days after discontinuing the study, even if they have had a successful vasectomy
- Ability and willingness to comply with the requirements of the study protocol
- The patient must have a diagnosis of CLL (CLL or SLL) that meets the criteria published in 2018 iwCLL
- Meeting the criteria for qualifying for therapy under the B.79 drug program
- Performance status 0-2 according to the ECOG scale
- Presence of indications for treatment according to the International Workshop on Chronic Lymphocytic Leukemia updating (the National Cancer Institute-Working Group (iwCLL)
- There are no contraindications to the use of the drug in accordance with the current Summary of Product Characteristics
- No hypersensitivity to any drug or mouse proteins or any of the excipients of the drug
Who cannot take part
- Disease progression during treatment, including transformation to a more aggressive lymphoma
- Occurrence of hypersensitivity symptoms to any of the drugs used or to mouse proteins or to any of the excipients of the drug, preventing continuation of treatment
- Occurrence of progressive multifocal leukoencephalopathy or severe skin reactions (toxic epidermal necrolysis, Stevens-Johnson syndrome) – in case of venetoclax therapy in combination with anti-CD20 antibody
- Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia – in the case of therapy with venetoclax as monotherapy or in combination with an anti-CD20 monoclonal antibody or ibrutinib
- The occurrence of diseases or conditions which, in the opinion of the attending physician, make further treatment impossible
- Lack of cooperation or failure to follow medical recommendations, including those regarding periodic check-ups to assess the effectiveness and safety of treatment, on the part of the beneficiary or his/her legal guardian
- Occurrence of unacceptable or life-threatening toxicity despite appropriate management
- Pregnancy or breastfeeding
Where in Poland
- Szpital Uniwersytecki nr 2 im dr Jana Biziela w BydgoszczyBydgoszcz, PolandNot yet recruiting
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w LodziLodz, PolandNot yet recruiting
- Uniwersytecki Szpital Kliniczny Nr 1 w LublinieLublin, PolandNot yet recruiting
- Uniwersytecki Szpital Kliniczny nr 4 w LublinieLublin, PolandNot yet recruiting
- Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu MedycznegoWarsaw, PolandNot yet recruiting
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, PolandNot yet recruiting
About the trial
What the trial wants to find out
Evaluation of the efficacy of venetoclax + rituximab (VR) treatment in clinical practice, based on the percentage of patients achieving MRD negativity (uMRD, MRD<10-4)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Phase IV study evaluating the efficacy and safety of the venetoclax + rituximab (VR) regimen in patients with relapsed chronic lymphocytic leukemia in Polish clinical practice
- Plain-language title
- Tests venetoclax with rituximab in adults with relapsed chronic lymphocytic leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 26 June 2026